ALTEROLA BIOTECH INC.: M&A transaction — Alterola sells Phytanix to Protagenic, plans to deregister; directors resign

ALTEROLA BIOTECH INC.

Alterola and EMC2 sold 100% of Phytanix to Protagenic for Protagenic common and preferred stock; combined ownership: 35% existing Protagenic, 65% Alterola/EMC2.
Alterola shareholders will be offered the option to swap ABTI shares for Protagenic shares; shareholder vote required by September 1, 2025.
Alterola intends to terminate SEC registration and become a privately held company to reduce costs.
Executive Chairman Tim Rogers, CEO David Hitchcock, CFO Nathan Thompson, and three independent directors resigned; Dominic Schiller and Colin Stott remain.

item 1.01 item 2.01 item 5.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

ALTEROLA BIOTECH INC. completed a disposition involving Protagenic Therapeutics, Inc. for shares of the Protagenic's common stock, Preferred Stock Payment Shares, Series D Payment Shares and Common Stock Warrants (closed 2025-05-16).

Action: disposition
Counterparty: Protagenic Therapeutics, Inc.
Consideration: shares of the Protagenic's common stock, Preferred Stock Payment Shares, Series D Payment Shares and Common Stock Warrants
Closing: 2025-05-16

Exact text from the filing

On May 16, 2025, Alterola, EMC2, and the Preferred Stockholders completed its business combination with Protagenic.

View on SEC.gov

Browse all m&a transactions →

Source: SEC EDGAR

accession 0001477932-25-004837

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.